Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

2 results

Results by year

Filters applied: . Clear all
Page 1
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis.
Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, Degar B, Garrington TP, Sevilla J, Putti MC, Fagioli F, Ahlmann M, Dapena Diaz JL, Henry M, De Benedetti F, Grom A, Lapeyre G, Jacqmin P, Ballabio M, de Min C. Locatelli F, et al. N Engl J Med. 2020 May 7;382(19):1811-1822. doi: 10.1056/NEJMoa1911326. N Engl J Med. 2020. PMID: 32374962 Free article. Clinical Trial.
Emapalumab was not associated with any organ toxicity. Severe infections developed in 10 patients during emapalumab treatment. Emapalumab was discontinued in 1 patient because of disseminated histoplasmosis. ...
Emapalumab was not associated with any organ toxicity. Severe infections developed in 10 patients during emapalumab treatment. …
Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: A pharmacometric model-based approach.
Jacqmin P, Laveille C, Snoeck E, Jordan MB, Locatelli F, Ballabio M, de Min C. Jacqmin P, et al. Br J Clin Pharmacol. 2022 May;88(5):2128-2139. doi: 10.1111/bcp.15133. Epub 2021 Dec 21. Br J Clin Pharmacol. 2022. PMID: 34935183 Free PMC article. Clinical Trial.
Emapalumab dosing was adjusted based on estimated IFNgamma-mediated clearance and HLH clinical and laboratory criteria. Frequent dosing and emapalumab dose adaptation were used to account for highly variable IFNgamma levels and potential target-mediated drug disposi …
Emapalumab dosing was adjusted based on estimated IFNgamma-mediated clearance and HLH clinical and laboratory criteria. Frequent dosi …